Effects of Tamoxifen and Raloxifene on Memory and Other Cognitive Abilities: Cognition in the Study of Tamoxifen and Raloxifene
Effects of Tamoxifen and Raloxifene on Memory and Other Cognitive Abilities: Cognition in the Study of Tamoxifen and Raloxifene
复制标题
DOI：
10.1200/jco.2008.21.0716
复制
发表时间：
2009-11-01
影响因子：
45.3
通讯作者：
Shumaker, Sally A.
中科院分区：
文献类型：
--
作者：
Legault, Claudine;Maki, Pauline M.;Shumaker, Sally A.
PurposeTo比较两种选择性雌激素受体调节剂，他莫昔芬和雷洛昔芬，对全球和特定领域的认知function.Patients和MethodsThe国家外科辅助乳腺和肠道项目的研究他莫昔芬和雷洛昔芬（星星）的研究是一项随机临床试验，他莫昔芬20毫克/天或雷洛昔芬60毫克/天的健康绝经后妇女乳腺癌的风险增加。被随机分配到星星的1,498名妇女年龄在65岁及以上，未被诊断为痴呆，并被纳入他莫昔芬和雷洛昔芬研究中的认知（Co-星星）试验，从星星招募开始后18个月开始。一个认知测试电池仿照使用的妇女健康倡议研究认知老化（WHISCA）。技术人员接受集中培训，以管理电池，并每6个月重新认证一次。对所有参与者和273名妇女谁完成了第一次认知电池之前，他们开始服用their medication.ResultsOverall，有两个治疗组之间的校正平均认知得分跨访视没有显着差异进行分析。在三次访视中，一些认知指标存在显著的时间效应。获得了类似的结果，为子集的妇女与真正的基线measures.ConclusionTamoxifen和雷洛昔芬的认知功能在绝经后妇女乳腺癌的风险增加与类似的模式。这些发现与WHISCA中激素治疗和安慰剂组认知功能模式之间的未来比较应提供他莫昔芬和雷洛昔芬对老年女性认知功能影响的更多见解。
PurposeTo compare the effects of two selective estrogen receptor modulators, tamoxifen and raloxifene, on global and domain-specific cognitive function.Patients and MethodsThe National Surgical Adjuvant Breast and Bowel Project's Study of Tamoxifen and Raloxifene (STAR) study was a randomized clinical trial of tamoxifen 20 mg/d or raloxifene 60 mg/d in healthy postmenopausal women at increased risk of breast cancer. The 1,498 women who were randomly assigned in STAR were age 65 years and older, were not diagnosed with dementia, and were enrolled onto the Cognition in the Study of Tamoxifen and Raloxifene (Co-STAR) trial, beginning 18 months after STAR enrollment started. A cognitive test battery modeled after the one used in the Women's Health Initiative Study of Cognitive Aging (WHISCA) was administered. Technicians were centrally trained to administer the battery and recertified every 6 months. Analyses were conducted on all participants and on 273 women who completed the first cognitive battery before they started taking their medications.ResultsOverall, there were no significant differences in adjusted mean cognitive scores between the two treatment groups across visits. There were significant time effects across the three visits for some of the cognitive measures. Similar results were obtained for the subset of women with true baseline measures.ConclusionTamoxifen and raloxifene are associated with similar patterns of cognitive function in postmenopausal women at increased risk of breast cancer. Future comparisons between these findings and patterns of cognitive function in hormone therapy and placebo groups in WHISCA should provide additional insights into the effects of tamoxifen and raloxifene on cognitive function in older women.